Scientists are crafting tiny proteins that can attack harmful bacteria while leaving human cells unharmed.  

They started by building computer models of both human and staphylococcal cell walls, then used these maps to search for short chains of amino acids that would fit snugly into the bacterial membrane but not the human one.  

A promising candidate, called RK7 and made of the sequence RKKYWLL, emerged from this virtual hunt.  

Further simulations showed that RK7 lodges itself into the staph membrane, disturbing its structure and killing the bacteria.  

The design process was aided by artificial intelligence, which predicted that RK7 would not be toxic to human tissues and would stay stable in the body.  

Lab tests confirmed these predictions: normal cells stayed healthy, while staph bacteria were largely destroyed.  

At a concentration of 62. 5 micrograms per milliliter, RK7 stopped more than 98 percent of the bacterial growth.  

This work demonstrates a new way to create targeted antibiotics by exploiting subtle differences between human and bacterial cell walls.  

The approach could guide future drug development against resistant infections.


# Scientists Design Targeted Protein Antibiotic

Scientists are crafting **tiny proteins** that can attack harmful bacteria while leaving human cells unharmed.

1. **Modeling the battlefield**  
   - Built computer models of both human and *Staphylococcus aureus* cell walls.  
   - Searched for short amino‑acid chains that fit into the bacterial membrane but not the human one.

2. **Discovery of RK7**  
   - Candidate sequence: `RKKYWLL`.  
   - Simulations showed RK7 embeds itself in the staph membrane, disrupting its structure and killing the bacteria.

3. **AI‑assisted safety checks**  
   - Artificial intelligence predicted RK7 would be non‑toxic to human tissues and stable in the body.

4. **Lab validation**  
   - Normal cells remained healthy; staph bacteria were largely destroyed.  
   - At **62.5 µg/mL**, RK7 inhibited over 98 % of bacterial growth.

**Implication**  
This work demonstrates a new way to create targeted antibiotics by exploiting subtle differences between human and bacterial cell walls, paving the way for future drug development against resistant infections.



New Peptide Hits Staph Bacteria Without Harming Human Cells

Actions